• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Newsletters |
  • Members Area |
  • Contact
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Alectos Therapeutics

Member Profile

Alectos Therapeutics discovers novel treatments to block the underlying progression of neurodegenerative diseases. Alectos identifies and develops innovative strategies to address complex neurological conditions, including Alzheimer’s disease and Parkinson’s disease.

The Alectos pipeline is focused on creating new therapeutics to treat patients living with these disorders. Our GBA2 program is a disease-modifying approach to correct lysosomal dysfunction in neurodegenerative diseases, including Parkinson’s disease. This program has recently been partnered with Biogen. Our OGA program is a strategy to prevent the accumulation and spread of toxic protein aggregates in the brain. Alectos partnered with Merck to pioneer the development of the first clinical OGA inhibitor. Alectos has repatriated this program and we are applying our deep knowledge and IP to advance novel OGA inhibitors as treatments for Alzheimer’s disease, frontotemporal dementia, and ischemic stroke. We welcome partnership inquiries regarding our OGA program and our advanced preclinical development candidates.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Drug Discovery
  • Neurological Diseases
  • Therapeutics
This member is looking for Academic Partnerships , Business Development
Company Stage Discovery Preclinical studies , Private Company

We are working On:

The Alectos pipeline is focused on creating new treatments for patients with neurological disorders, including those living with Parkinson’s and Alzheimer’s diseases. Our preclinical programs aim to identify and develop novel small molecules as potential disease-modifying therapies. Glucocerebrosidase 2 (GBA2) inhibition has emerged as a novel therapeutic strategy to enhance lysosomal function in neurodegenerative diseases. In the Alectos GBA2 program, we have identified molecules that possess drug-like properties including good potency, selectivity, pharmacokinetics, and CNS penetrance. Our lead compound, AL01811, is a selective GBA2 inhibitor with first-in-class potential as an oral disease-modifying treatment for patients with Parkinson’s disease. This program has recently been partnered with Biogen. Inhibition of O-GlcNAcase (OGA) is a promising approach for the treatment of several neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, and ischemic stroke. Alectos previously partnered with Merck to advance the first clinical OGA inhibitor and OGA PET ligand to phase 1 studies, where they were found to be safe and well-tolerated. Alectos has repatriated this program and we are focused on advancing a novel OGA development candidate, enabled by our OGA PET ligand to measure target engagement in the clinic. The Alectos OGA program builds on our deep knowledge and scientific leadership in this area. We welcome partnership inquiries regarding our OGA inhibitor program and our advanced preclinical development candidates.

Member Profile

Biotechnology, Therapeutics

Alectos Therapeutics

  • Website www.alectos.com
  • Phone +1 (604) 628 7129
  • Email info@alectos.com
  • Address
    8999 Nelson Way
    Burnaby, BC
    V5A 4B5
  • Leadership Contact
    Ernest McEachern, President & CEO
    Follow us:
  • Twitter
  • LinkedIn
  • News
  • Jobs

June 6, 2022

Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease

No current content.

  • Twitter
  • Linkedin
Tweets by Alectos Therapeutics
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us